Key result
IV beta-blockers linked to ~44% higher 30-day mortality in STEMI patients undergoing primary PCI.
Why the study?
Does intravenous beta-blocker therapy reduce short-term mortality in patients with STEMI treated with primary PCI and DAPT?
Observational (n=16,909)
Yes
Does intravenous beta-blocker therapy reduce short-term mortality in patients with STEMI treated with primary PCI and DAPT?
Effect estimate: HR 1.44 (95% CI 1.14-1.83)
In patients with STEMI undergoing primary PCI, the use of intravenous beta-blockers is associated with increased short-term mortality, lower LVEF at discharge, and a higher risk of cardiogenic shock.
No takes yet. Share an insight, caveat, or question.
May warrant caution with IV beta-blockers in STEMI primary PCI; challenges weak prior evidence for benefit and leaves open randomized confirmation.
Mohammad et al. (2017) conducted an observational in ST-segment elevation myocardial infarction (STEMI) (n=16,909). Intravenous (IV) beta-blocker therapy vs. No IV beta-blocker therapy was evaluated on Mortality within 30 days (HR 1.44, 95% CI 1.14-1.83). Intravenous beta-blocker therapy in STEMI patients treated with primary PCI was associated with higher 30-day all-cause mortality (HR 1.44; 95% CI 1.14-1.83).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: